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The Raf-1 serine/threonine kinase is a key protein that is
implicated in the transmission of many growth and cell
survival signals. In the present study we demonstrate that
apoptosis of hematopoietic cells induced by IL-3-depriva-
tion is associated with the cleavage of Raf-1, resulting in
the separation of the N-terminal regulatory domain and
the C-terminal kinase domain. Raf-1 cleavage specifically
occurs upon triggering of the mitochondrial death path-
way, and coincides with the activation of specific caspases.
Moreover, Bcl-2 overexpression or treatment with the
caspase inhibitor z-VAD.fmk completely prevented Raf-1
cleavage, whereas caspase inhibition by treatment of cells
with Ac-DEVD.fmk or z-IETD.fmk, or CrmA over-
expression had no effect. Furthermore, in vitro cleavage
studies indicate that caspase-9, which is the apical
protease in the mitochondrial death pathway, is able to
cleave Raf-1 at position D279. Cell fractionation studies
showed that the Raf-1 C-terminal fragment that is
generated upon IL-3 withdrawal is localized predomi-
nantly to the mitochondria. In addition, constitutive
expression of this C-terminal Raf-1 fragment fused to a
mitochondrial targeting sequence in Ba/F3 pre-B cells
significantly delays apoptosis induced by IL-3 withdrawal.
These results suggest an important role for caspase-9
mediated cleavage of Raf-1 in the negative feedback
regulation of hematopoietic cell apoptosis induced by
growth factor withdrawal.
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Introduction
A common feature of apoptosis is the activation of
caspases. These intracellular aspartic acid-directed
proteases are synthesized as inactive precursors that
are activated by dimerization or proteolytic processing
(Boatright et al., 2003; Boatright and Salvesen, 2003).
They act either as initiators (caspases-2, -8, -9) in
response to apoptotic signals, or as effectors (caspases-3,
-6, -7) that finally cleave a number of vital proteins
(Earnshaw et al., 1999). Many apoptotic responses are
initiated by activation of the apical caspases-8 or -9, the
former by recruitment to ligated cell surface receptors
belonging to the tumor necrosis factor receptor-1 family,
and the latter by recruitment to Apaf-1 in the presence
of dATP following delivery of cytochrome c from
mitochondria (Boldin et al., 1996; Muzio et al., 1996;
Li et al., 1997). In this regard, at least two major
pathways for caspase activation and apoptosis have
been delineated, including an ‘extrinsic’ pathway trig-
gered by the TNF family death receptors and an
‘intrinsic’ pathway activated by damage to mitochondria
leading to cytochrome c release into the cytosol.
However, apoptotic stimuli do not often act through a
single signaling pathway. In so-called ‘type II’ cells, the
death receptor and the mitochondrial pathway are
interconnected via caspase-8-mediated translocation of
truncated Bid (tBid) to mitochondria, where tBid
triggers cytochrome c release into the cytosol (Li et al.,
1998; Luo et al., 1998; Scaffidi et al., 1998).
Raf-1 is a serine/threonine kinase implicated in cell
survival. Structural and functional studies have shown
that Raf-1 is composed of two distinct domains, an N-
terminal regulatory domain (containing the conserved
regions CR1 and CR2) and a C-terminal kinase domain
(constituting the third conserved region, CR3). The
amino-terminal domain suppresses the catalytic activity
of Raf-1, and its deletion constitutively activates Raf-1
(Stanton et al., 1989; Heidecker et al., 1990).
Raf-1 was originally described as the initiator of a
mitogen-activated protein kinase (MAPK) cascade
involved in the regulation of cell proliferation and
differentiation (Davis, 1994; Robinson and Cobb, 1997).
Surprisingly, three independent Raf-1 knockouts in
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mice, generated with different gene targeting strategies,
showed normal MAPK activation in embryonic fibro-
blasts (MEFs), suggesting that Raf-1 may be dispen-
sable for MAPK signaling (Wojnowski et al., 1998;
Huser et al., 2001; Mikula et al., 2001). However, based
on the increase in apoptosis in mutant embryonic tissues
and the increased sensitivity of Raf-deficient mouse
embryonic fibroblasts to apoptotic agents, it was
concluded that the primary function of Raf-1 is to
protect cells from apoptosis independently of the
MAPK cascade. Consistent with the observations in
the Raf-1 / animals, inactivation of the c-Raf-1 gene
in macrophages by Cre-loxP-mediated recombination
induces hypersensitivity to pathogen-induced apoptosis,
independently of MEK/ERK (Jesenberger et al., 2001).
Several mechanisms have been proposed to explain
the antiapoptotic function of Raf-1. It has been
suggested that Raf-1 may promote cell survival by
antagonizing the proapoptotic apoptosis signal-regulat-
ing kinase 1 (ASK1) through a direct inhibitory
interaction with the N-terminal domain of ASK1 (Chen
et al., 2001). It was also reported that Raf-1 translocates
to the mitochondria in response to survival stimuli,
where it mounts an antiapoptotic response indepen-
dently of ERK activation (Wang et al., 1996; Salomoni
et al., 1998; Peruzzi et al., 1999; Alavi et al., 2003). It was
suggested that, when located to the mitochondria, Raf-1
suppresses cell death by inactivating the proapoptotic
Bcl-2 family member Bad (Wang et al., 1996; Salomoni
et al., 1998). Phosphorylation of Bad by protein kinases
such as Raf-1 or Akt (Wang et al., 1996; Datta et al.,
1997) leads to the dissociation of Bad from the
prosurvival Bcl-XL protein, and sequestration of Bad
in an inactive complex with 14-3-3 proteins in the
cytosol (Zha et al., 1996).
Here, we report that Raf-1 is rapidly cleaved by
caspase-9 during apoptosis of hematopoietic cells
induced by IL-3 withdrawal. Raf-1 processing cleaves
off the N-terminal regulatory domain, leaving an intact
C-terminal kinase domain (Raf-1-Ct) that is predomi-
nantly localized to the mitochondria. Furthermore,
constitutive expression of mitochondria-targeted Raf-
1-Ct significantly delays apoptosis of pre-B cells induced
by IL-3 withdrawal. These results suggest an important
role for caspase-9 mediated cleavage of Raf-1 as a
negative feedback regulatory mechanism of hemato-
poietic cell apoptosis.
Results
Raf-1 is efficiently cleaved in hematopoietic cells
undergoing apoptosis through the mitochondrial death
pathway
The antiapoptotic potential of Raf-1 led us to evaluate
the fate of this protein kinase during apoptosis triggered
by the intrinsic (growth factor withdrawal) and extrinsic
(death receptor) death pathways. It has been shown that
mitochondria play an important role in the early events
of the apoptotic process induced by withdrawal of
cytokines in cytokine-dependent hematopoietic cells.
Release of cytochrome c from the mitochondrial
intermembrane space into the cytoplasm and loss of
mitochondrial membrane potential have been demon-
strated in IL-3-deprived pre-B cells (Vander Heiden
et al., 1997; Bojes et al., 1999). In the present study, we
used the IL-3 dependent pre-B cell line Ba/F3. Upon IL-3
withdrawal, Ba/F3 cells were arrested in the G1 phase
of the cell cycle and died apoptotically, as demonstrated
by DNA hypoploidy and proteolytic activation of
caspase-3. Ba/F3 cell lysates were prepared at various
times after IL-3 withdrawal for immunoblot analysis
with anti-Raf-1 antibodies raised against a peptide
corresponding to the C-terminus of Raf-1. Within 12 h
after IL-3 withdrawal, at which time 10% of the cells
were hypoploid, a faint band of B40 kDa representing
the C-terminal fragment of Raf-1 could be detected
(Figure 1a). The abundance of the C-terminal fragment
increased with time, concomitantly with a decrease of
the full-length 74 kDa Raf-1 protein. In addition to the
predominant cleavage product of B40 kDa, a less
abundant Raf-1-fragment of B48 kDa was also ob-
served. As the latter is presumably an intermediate
cleavage product, only the generation of the B40 kDa
fragment was investigated further in detail. A similar
Raf-1-specific B40 kDa-fragment was also generated
during apoptosis induced by IL-3 withdrawal of the
IL-3-dependent promyeloid FDCP-1 cell line (Figure 1b).
To determine whether proteolysis of Raf-1 also occurs
in response to other intrinsic apoptotic stimuli, the Ba/
F3 cells were exposed to puromycine (1 mg/ml), an
inhibitor of translation elongation. The cell death
response and the kinetics of Raf-1-cleavage induced by
puromycine were similar to those induced by growth
factor withdrawal (Figure 1c).
To determine if Raf-1 is also cleaved upon triggering
of the extrinsic death pathway, its cleavage in death
receptor-mediated apoptosis was examined in L929sAh-
Fas and L929sAhFas.Bcl-2 cells. Stimulation of
L929sAhFas cells with agonistic antibodies against Fas
induces activation of caspase-8, which, in addition to
directly activating executioner caspases, initiates the
mitochondrial death pathway via the generation and
translocation of tBid to the mitochondria (Denecker
et al., 2001). Overexpression of the antiapoptotic Bcl-2
protein in L929sAhFas.Bcl-2 cells specifically inhibits
the mitochondrial branch of the Fas pathway, by
blocking cytochrome c release from the mitochondria
(Denecker et al., 2001). Figure 2a shows that in
L929sAhFas cells stimulated with anti-Fas, Raf-1
cleavage occurs at a much later stage of the apoptotic
response (reflected by the % hypoploid cells) than in
Ba/F3 cells deprived of IL-3. Proteolytic activation of
executioner caspase-3 in the anti-Fas stimulated
L929sAhFas cells was detectable much earlier than the
processing of Raf-1 (Figure 2a). Raf-1-cleavage was
completely inhibited during the cell death response in
anti-Fas stimulated L929sAhFas.Bcl-2 (Figure 2b). All
together, these results indicate that cleavage of Raf-1
into the B40 kDa C-terminal fragment involves the
mitochondria-dependent cell death pathway.
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Processing of Raf-1 during apoptosis induced by growth
factor withdrawal is mediated by caspase-9
To investigate the potential role of specific caspases in
the cleavage of Raf-1, we first attempted to identify the
caspases that are proteolytically activated during
apoptosis induced by IL-3 withdrawal in Ba/F3 cells
(Figure 3a). Processing of procaspase-9 into p35 and p12
subunits and caspase-9 enzymatic activity were detected
in the cytosolic extracts as early as 12 h after IL-3
depletion, and coincided with the time of Raf-1
cleavage. The kinetics of proteolytic activation of pro-
caspases-3 and -7 were similar to those of pro-caspase-9.
In contrast, caspase-8 was cleaved at a later stage. To
further investigate which of the activated caspases could
be involved in the cleavage of Raf-1, we analysed the
effects of several caspase peptide inhibitors
(z-VAD.fmk, Ac-DEVD.fmk, z-IETD.fmk), as well as
the overexpression of the viral caspase inhibitory protein
CrmA or the antiapoptotic protein Bcl-2, on Raf-1
cleavage in Ba/F3 cells. Incubation of Ba/F3 cells with
the broad-spectrum caspase inhibitor z-VAD.fmk en-
tirely prevented the cleavage of Raf-1 (Figure 3b, lane 3).
On the other hand, Ac-DEVD.fmk and z-IETD.fmk,
which display some specificity for caspase-3-like and
caspase-8-like caspases, respectively, did not inhibit Raf-1
processing (Figure 3b, lanes 4 and 5). In line with these
results, overexpression of the caspase-1 and caspase-8-
specific inhibitor CrmA also did not block Raf-1
cleavage in response to IL-3 withdrawal (Figure 3c,
lane 4). In contrast, Ba/F3 cells overexpressing Bcl-2
showed no Raf-1 cleavage (Figure 3c, lane 3). All
together, these studies indicate that Raf-1 cleavage is
dependent on the activation of a z-VAD.fmk-sensitive
but Ac-DEVD.fmk- or z-IETD.fmk-insensitive caspase,
the activation of which can be inhibited by Bcl-2
overexpression. Taking into account the activation of
caspase-9 in IL-3 deprived cells, its z-VAD.fmk sensi-
tivity and its positioning downstream of the mitochon-
dria, caspase-9 is a likely candidate for the Raf-1-
cleaving caspase.
To further investigate caspase-9’s involvement in Raf-1
processing, in vitro translated and 35S-methionine
labeled Raf-1 was incubated with purified recombinant
active caspase-9, and in vitro Raf-1 cleavage was
monitored by SDS–polyacrylamide gel electrophoresis.
Caspase-9 cleaved Raf-1 into two distinct fragments of
B40 and B35 kDa (Figure 4a). The size of the higher
molecular mass band corresponds to the length of the
C-terminal fragment observed in apoptotic Ba/F3 and
FDCP-1 cells, further suggesting that caspase-9 is
responsible for Raf-1 cleavage in Ba/F3 cells. The
35 kDa product that is generated in vitro most likely
corresponds to the N-terminal part of Raf-1. Three
potential caspase cleavage sites that could result in
the generation of fragments with molecular masses
Figure 1 Raf-1 is cleaved following IL-3 withdrawal and puromycine treatment in Ba/F3 cells and FDCP-1 cells. Cleavage of Raf-1
was examined in IL-3 deprived Ba/F3 cells (a) and FDCP-1 cells (b), as well as in puromycine (1mg/ml) treated Ba/F3 cells (c). At the
indicated time points, cell lysates were resolved using 10% SDS–PAGE and subsequently analysed by immunoblotting using a
polyclonal anti-Raf C-terminal antibody and an anti caspase-3 antibody. Arrowheads indicate full-length Raf-1 and the B40 kDa
cleavage product. Percentages of hypoploid cells as a measure for apoptosis are indicated at the bottom of each panel
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corresponding to those described above were identified
in the Raf-1 sequence, at positions D273, D279 and
D337 (Figure 4b). To determine which of these sites
corresponds to the caspase-9 cleavage site, each Asp
residue was mutated to Ala, and the in vitro sensitivity of
the respective Raf-1 mutants to caspase-9-mediated
proteolysis was analysed. Caspase-9-mediated cleavage
was completely abolished in the D279A mutant, whereas
the D273A and D337A mutants were still processed
(Figure 4c). Note that the 40 kDa cleavage product runs
slightly slower in the case of the Raf-1 mutants when
compared to wild-type Raf-1, which is due to the
presence of an E-tag peptide epitope (GAPVPYPD-
PLEPRAA) that was fused to the C-terminus of the
Raf-1 mutants.
To investigate whether the D279A mutant is pro-
tected from cleavage in IL-3 deprived Ba/F3 cells, we
stably expressed this mutant (Raf-1E-D279A) and the
wild-type Raf protein (Raf-1E) in Ba/F3 cells and
analysed their cleavage in IL-3-deprived transfectants
(Figure 4d). Whereas the apoptotic responses upon IL-3
withdrawal in the Ba/F3-Raf-1E and Ba/F3-Raf-1E-
D279A transfectants are comparable, as revealed by
proteolytic activation of caspase-3, processing of the
Raf-1E-D279A mutant is suppressed. This result sug-
gests that the D279 caspase-9 cleavage site is also used in
dying cells. However, some residual cleavage of the
mutant could still be detected after 36 h of IL-3
deprivation, suggesting that in addition to the D279
cleavage site also (an)other cleavage site(s) (is) are (as
for instance D273 or D337) maybe involved in Raf-1
processing. All together, the above observations clearly
indicate a role for caspase-9 in the cleavage of Raf-1 at
position D279 during apoptosis of hematopoietic cells
induced by growth factor withdrawal.
As indicated above, the caspase-9 mediated cleavage
of Raf-1 separates the N-terminal regulatory domain
and the C-terminal kinase domain (Figure 4b). Raf-1
was originally described as an initiator of the MAPK
cascade, leading among others to Erk1/2 phosphoryla-
tion and the downstream activation of promotors
containing a serum responsive element (SRE). To
investigate whether the Raf-1-Ct fragment is still
enzymatically active, we ectopically expressed Raf-1,
Raf-1-Ct and their respective kinase defective (K375A)
mutants in HEK293T cells and determined the phos-
phorylation state of the Erk1/2 kinase by immunoblot-
ting with phospho-Erk-specific antibodies. In addition,
we assessed SRE-mediated gene induction by means of
the cotransfected reporter plasmid pSRE-Luc, in which
the expression of a luciferase reporter gene is under the
control of an SRE (Figure 5). Immunoblotting of total
cell lysates revealed that Erk1/2 phosphorylation was
enhanced in extracts from cells transfected with either
Raf-1 or Raf-1-Ct. However, the increase was most
prominent in the Raf-1-Ct expressing lysates, indicating
that the cleavage product exerts a stronger kinase
activity than the full-length Raf-1 kinase (Figure 5a).
In line with this result, SRE-driven luciferase reporter
activity was found to be 5- and 2-fold higher in cells
expressing Raf-1-Ct and Raf-1, respectively, as com-
pared with that of cells transfected with the kinase
defective counterparts (Figure 5b). These results are
consistent with previous work showing that the
N-terminal domain suppresses the catalytic activity of
Raf-1, and its deletion constitutively activates
Raf-1 (Stanton et al., 1989; Heidecker et al., 1990).
Raf-1-Ct preferentially localizes to the mitochondria
where it can enhance cellular resistance to apoptosis
Raf-1 has been shown to efficiently suppress apoptotic
cell death via a process that requires its translocation to
the mitochondria (Wang et al., 1996; Salomoni et al.,
1998; Majewski et al., 1999). To further investigate the
role of caspase-9-mediated cleavage of Raf-1 during
apoptosis induced by growth factor withdrawal, we
examined Raf-1 expression in mitochondrial and cyto-
solic fractions of growing and IL-3-deprived Ba/F3 cells.
Mitochondrial fractions were prepared by Percoll
gradient centrifugation. Purity of the mitochondrial
and the cytosolic fractions was judged by Western blot
analysis of the mitochondrial marker protein cyto-
chrome oxidase subunit IV (COX IV) and the cytosolic
Figure 2 Cleavage of Raf-1 requires activation of the mitochondrial death pathway. (a) L929sAhFas cells and (b) L929sAhFas.Bcl-2
cells were stimulated with anti-Fas antibodies (100 ng/ml) for the indicated periods of time. Cellular proteins were separated by SDS–
PAGE, and the proteolytic processing of Raf-1 and caspase-3 was detected by immunoblotting. Arrowheads indicate full-length Raf-1
and the B40 kDa cleavage product. Induction of apoptosis was determined by measuring the percentage of hyploid cells
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Erk1/2 MAP kinases, respectively. COX IV was
detectable exclusively in the mitochondrial fraction,
whereas the Erk1/2 MAP kinases were found mainly in
the cytosolic fraction (Figure 6). Immunoblotting with
anti-Raf-1 antibodies showed that the great majority of
full-length Raf-1 was present in the cytosol of prolifer-
ating cells, and only a small part resided in the
mitochondria. In contrast, IL-3 depletion resulted
in an enrichment of Raf-1 in the mitochondrial frac-
tion. Interestingly, the caspase-9 induced C-terminal
Figure 3 Cleavage of Raf-1 coincides with caspase activation and is blocked by Bcl-2 and z-VAD.fmk. (a) Raf-1 cleavage coincides
with caspase activation during apoptosis of Ba/F3 cells induced by IL-3 deprivation. Total lysates of cells deprived of IL-3 for the
indicated times were assayed for caspase-9 activity using a fluorogenic peptide substrate (Ac-LEHD-amc) as described under ‘Material
and methods’ (upper panel) and resolved using SDS–PAGE for immunoblotting with the polyclonal anti-Raf-1 or anti-caspase
antibodies as indicated (lower panels). (b) Processing of Raf-1 in the presence of peptide caspase inhibitors. Cells were grown in the
presence of IL-3 (lane 2) or deprived of IL-3 for 16 h in the absence (lane 1) or presence of 200mM z-VAD.fmk (lane 3), Ac-DEVD.fmk
(lane 4) or z-IETD.fmk (lane 5). Proteolytic processing of Raf-1 was detected by immunoblotting with polyclonal anti Raf-1
antibodies. (c) Effects of Bcl-2 and CrmA overexpression on cleavage of Raf-1 induced by IL-3 deprivation. Ba/F3 cells stably
overexpressing Bcl-2 (Ba/F3-Bcl-2; lane 3) or CrmA (Ba/F3-CrmA; lane 4) were depleted of IL-3 for 16 h. Stable transfectants which
express only the puromycine resistance gene (Ba/F3-puro) served as a control (lanes 1 and 2). Lysates were analysed by
immunoblotting with anti-Raf-1 polyclonal antibodies
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fragment of Raf-1 (Raf-1-Ct) was predominantly pre-
sent in the mitochondrial fraction (Figure 6).
It has been shown that mitochondrial targeting of a
Raf-1 deletion mutant lacking the N-terminal domain
(D26-303) delays apoptotic cell death in IL-3 deprived
32D.3 cells (Wang et al., 1996). To investigate whether
Raf-1-Ct localized in the mitochondria has the same
effect on cell survival, we used Ba/F3 cells stably
transfected with an expression vector encoding Raf-1-
Ct fused with the transmembrane domain of the yeast
outer mitochondrial membrane protein Mas70p
(M-Raf-1-Ct), for targeting to mitochondria (Hase
et al., 1984). In addition, we also used cells transfected
with a similar construct encoding a kinase defective
K375A Raf-1-Ct mutant. Immunoblot analysis of
lysates prepared from these cells confirmed the expres-
sion of all transfected proteins, and confocal microscopy
of fixed cells confirmed mitochondrial localization of M-
Raf-1-Ct (data not shown). Kinetics of Ba/F3 cell death
in response to IL-3 depletion was determined by
measuring DNA hypoploidy (Figure 7a), and by
assessment of caspase-3 activity (Figure 7b). The latter
was determined by measuring the rate of Ac-DEVD-
amc cleavage in cell lysates. Ba/F3 cells that were
Figure 4 Cleavage of Raf-1 and Raf-1 mutants by caspase-9. (a, c) In vitro cleavage of Raf-1 and Raf-1 mutants by caspase-9. In vitro
translated and 35S-labeled Raf-1 (a, c) and E-tagged Raf-1 mutants (Raf-1E) (c) were incubated with recombinant caspase-9 for 1 h at
371C. Reactions were then resolved on 10% (a) or 15% (c) SDS–polyacrylamide gels followed by autoradiography. Arrowheads
indicate bands corresponding to the N-terminal (Nt) and C-terminal (Ct) cleavage products of Raf-1. (b) Schematic representation of
the primary structure of Raf-1 and the potential cleavage sites for caspase-9. Numbers indicate the position of amino acid residues.
CR1, CR2 and CR3 are three regions that are highly conserved among Raf proteins: CR1 is rich in cysteine residues, CR2 is rich in
serine/threonine residues, and CR3 is the kinase domain. Aspartic acid residues that were mutated in the present study are indicated in
bold. The arrowhead indicates the cleavage site for caspase-9. (d) Cleavage of Raf-1 and Raf-1E-D279A during apoptosis of Ba/F3
cells induced by IL-3 deprivation. Total lysates of Ba/F3 cells stably expressing Raf-1E (left panel) or Raf-1E-D279A (right panel), and
deprived of IL-3 for the indicated times, were subjected to Western blotting with anti-E tag and anti-caspase-3 antibodies. Arrowheads
indicate full-length Raf-1 and the B40 kDa cleavage product
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transfected only with the plasmid containing the
puromycine (puro) resistance gene, and cells that were
transfected with Bcl-2 were used as negative and positive
controls, respectively. Cell death was significantly
delayed in Ba/F3 cells expressing Bcl-2 or M-Raf-1-Ct,
but not in those expressing Raf-1-Ct. Moreover, none of
the kinase inactive versions of Raf-1, irrespective of their
mitochondrial localization, could delay the apoptotic
response. These results indicate that mitochondrial
localization of the caspase-9-induced Raf-1-Ct fragment
prolongs survival of Ba/F3 cells in the absence of IL-3.
Discussion
The Raf-1 serine/threonine kinase is an important signal
transducing molecule that functions in many growth
and developmental pathways. Raf-1 activation is a
complex process involving changes in subcellular
localization, inter- and intramolecular interactions,
and phosphorylation events (reviewed by Chong et al.,
2003). In this report we demonstrate that Raf-1 is
rapidly processed from its 74 kDa full-length form into a
C-terminal fragment ofB40 kDa (Raf-1-Ct) in the IL-3-
dependent Ba/F3 pre-B cell line induced to undergo
apoptosis by IL-3 withdrawal. This cleavage requires
activation of the mitochondrial death pathway and is
mediated by the apical caspase-9 protease. Caspase-9
cleaves Raf-1 at position D279, which is conserved in
human and mouse Raf-1. D279 and its context do not fit
the proposed consensus motif for a caspase-9 cleavage
site (Thornberry et al., 1997; Garcia-Calvo et al., 1999),
but the autocatalytic cleavage site (PEPDA) in caspase-9
itself also exhibits poor similarity with the consensus
sequence (Stennicke et al., 1999). Previous work has
shown that Raf-1 contains an autoinhibitory domain
within the first 330 amino acids of its N-terminus (Cutler
et al., 1998; Chong and Guan, 2003). Deletions of the
N-terminal regulatory domain have been found in
several activated forms of Raf genes detected in certain
neoplastic human cells (Stanton and Cooper, 1987),
resulting in a constitutively active kinase domain that is
comparable to the oncogenic v-Raf protein (Cleveland
et al., 1994). The mechanism whereby the catalytic
domain of c-Raf-1 is released from the autoinhibitory
domain is still largely unknown, although a role for
phosphorylation of the kinase domain by p21-activated
kinase 1 and Src has been demonstrated (Tran and
Frost, 2003). Our data indicate that caspase-9 mediated
cleavage of Raf-1 at D279, thus separating the
Figure 5 The caspase-9 induced C-terminal fragment of Raf-1
shows increased activity compared to full-length Raf-1. (a) Erk1/2
phosphorylation by Raf-1. Expression vectors encoding the wild-
type Raf-1 kinase (Raf-1), the C-terminal cleavage product (Raf-1-
Ct) and their kinase defective mutants (Raf-1 (K375A), Raf-1-Ct
(K375A)) were transiently transfected in HEK293T cells. After
24 h, cells were lysed and cellular proteins were separated by SDS–
PAGE. Expression levels of transfected E-tagged proteins were
evaluated by immunoblotting with anti-E-tag antibodies (upper
panel). The phosphorylation level of Erk1/2 in the various cell
lysates was analysed by immunoblotting with antibodies specific
for Thr202/Tyr204 phosphorylated Erk1/2 (Erk1/2-P; middle
panel). Total Erk1/2 (Erk1/2-T) levels were revealed by anti-
Erk1/2 antibodies (lower panel). (b) Induction of SRE-dependent
gene expression by Raf-1. The expression vectors encoding the
wild-type Raf-1 kinase (Raf-1), the cleavage product (Raf-1-Ct)
and their kinase defective mutants (Raf-1 (K375A), Raf-1-Ct
(K375A)) were cotransfected with the pSRE-Luc plasmid (Path-
Detect, Stratagene), and with the pSV-Sport b-galactosidase
plasmid. The latter was used to correct for variation of transfection
efficiency. After 24 h, cells were lysed and the activities of luciferase
and b-galactosidase were measured. Luciferase activity was
normalized to the b-galactosidase activity. Bars represent the
average (n¼ 3)7s.d. of normalized luciferase activities. Bars are
representative of two independent transfection experiments
Figure 6 Raf-1-Ct is mainly localized to the mitochondria in IL-3
deprived Ba/F3 cells. Immunoblots of cytosolic fractions (C) and
mitochondral fractions (M) of growing (ctrl) and IL-3 deprived (–
IL-3) Ba/F3 cells (see ‘Material and methods’ for details). Equal
amounts of protein were loaded in each lane (50mg) and probed
with antibodies against cytochrome oxidase subunit IV (COX IV),
Erk1/2, or Raf-1
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N-terminal regulatory domain from the intact C-terminal
kinase domain, might be another mechanism to relieve
autoinhibition. It should also be mentioned that relief of
autoinhibition is not sufficient for full kinase activation
and that this activation still relies on activating
phosphorylation mechanisms (Chong and Guan,
2003). A similar mechanism of proteolytic kinase
activation by caspases has been demonstrated for a
number of other kinases including protein kinase C delta
(Emoto et al., 1995) and p21-activated kinase 2
(Bokoch, 1998).
Several lines of evidence indicate an important role
for Raf-1 in cell survival signaling (reviewed by
Troppmair and Rapp, 2003). However, our knowledge
of the molecular mechanisms by which Raf-1 assures cell
survival is still very limited. Evidence for a critical role
of mitochondria in Raf-1 survival signaling has been
supported by the demonstration of a mitochondrial Raf-
1 survival pathway, which involves Bcl-2 driven
mitochondrial translocation of the kinase and apoptosis
suppression by a mechanism, which leads to the
phosphorylation and thereby inactivation of the proa-
poptotic Bcl-2 family protein Bad (Wang et al., 1996;
Salomoni et al., 1998). However, protection by mito-
chondrial Raf-1 also occurs in cell lacking the expression
of Bcl-2 or Bad, implying that Raf-1 may maintain cell
survival via Bcl-2/Bad independent pathways. In this
context, a role for voltage-dependent anion channel
(VDAC) has already been suggested (Le Mellay et al.,
2002). So far, we have no clear understanding how Raf-
1 gets activated at the mitochondria or even if Raf-1
activation has to occur at the mitochondria. Interest-
ingly, we could demonstrate that the caspase-9-gener-
ated Raf-1 C-terminal kinase fragment is predominantly
localized in the mitochondrial fraction of IL-3 depleted
Ba/F3 cells. The increased expression of full-length Raf-
1 in the mitochondria of deprived cells, and several
reports on mitochondrial localization of caspase-9
suggest a model in which Raf-1 is translocated to the
mitochondria where it is cleaved by caspase-9 (Kra-
jewski et al., 1999; Susin et al., 1999; Costantini et al.,
2002; Potokar et al., 2003). However, we were unable to
detect caspase-9 in the mitochondrial fraction of IL-3
deprived Ba/F3 cells (van Loo et al., 2002), suggesting
that Raf-1 is cleaved by caspase-9 in the cytoplasm and
then translocates to the mitchondria. Using fusion of
the C-terminal fragment of Raf-1 with a mitochondrial
targeting sequence derived from the Mas70p protein,
we could show that the caspase-9 generated Raf-1
catalytic fragment needs to localize to the mitochondria
in order to fulfill its antiapoptotic function. Since it
was shown that the C-terminal half of Raf-1 is sufficient
for co-immunoprecipitation with Bcl-2 (Wang et al.,
1994), mitochondrial recruitment of the endogenous
caspase-9 generated Raf-1 fragment could still be
mediated by Bcl-2.
In conclusion, our results suggest an important role
for caspase-9 mediated proteolytic activation of Raf-1 in
the negative feedback regulation of hematopoietic cell
apoptosis induced by growth factor depletion. In certain
conditions, for instance during temporary but poten-
tially lethal lack of survival factors, relief of Raf-1
autoinhibition by caspase-9 mediated release of the Raf-
1 N-terminal regulatory domain might help to overcome
the critical period by blocking the proapoptotic signal at
the mitochondria. Refinement of this model remains an
area for further study.
Materials and methods
Plasmid constructs
Human Raf-1 cDNA was inserted as an EcoR1 fragment into
an EcoR1-opened pSV-Sport expression plasmid (Invitrogen,
Figure 7 Mitochondrial targeting of Raf-1-Ct enhances Ba/F3 cell
survival in the absence of IL-3. Ba/F3 cells stably expressing a
nontargeted or a mitochondria-targeted C-terminal Raf-1 fragment
(Raf-1-Ct or M-Raf-1-Ct, respectively) or their kinase-defective
mutants (Raf-1-Ct-K375A or M-Raf-1-Ct-K375A, respectively)
were cultured without IL-3 for the indicated times. Cells
transfected with Bcl-2 or only the puromycine resistance gene
(Puro) were used as positive and negative control, respectively. (a)
The percentage of hypoploid cells, determined by flow cytometry of
propidium iodide-stained nuclei, is indicated as a measure for
apoptosis. The mean values (7s.d.) of triplicate cultures are
shown. (b) Cell extracts were assayed for caspase-3 activity based
on the rate of Ac-DEVD-amc cleavage. Results are representative
of three independent experiments
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San Diego, CA, USA) to obtain pSV-Sport-Raf-1. Raf-1E-
D273A, Raf-1E-D279A, Raf-1E-D337A and Raf-1E-K375A
were generated by overlap PCR using pSV-Sport-Raf-1 as a
template, and cloned as EcoR1/Not1 fragments in frame with a
C-terminal E-tag into pSV-Sport-E tag (Cornelis et al., 2000).
Overlap primers containing the indicated mutations were as
follows: Mutant D273A: 50-CTGCCTGTGGCCAGCAG
GATGATTGAGGATGCAATTCGAAGT-30 and 50-ACTTC
GAATTGCATCCTCAATCATCCTGCTGGCCACAGGCA









The caspase-9 generated Raf-1 C-terminal domain (Raf-1-
Ct) and the corresponding kinase inactive mutant Raf-1-Ct-
K375A were generated by PCR using, respectively, pSV-Sport-
Raf-1E and pSV-Sport-Raf-1E-K375A plasmids as templates,
and the primers 50-CGGGGTACCGCAATTCGAAGTCA
CAGCGAATCAGCC-30 and 50-TTACCGCTCGAGTCTAT
GCGGCACGCGGTTCCAGCGGATC-30. The obtained
Kpn1/Xho1 Raf-1-specific fragments were subsequently cloned
in a Kpn1/Sal1-opened pCAGGS expression vector.
Mitochondria-targeted Raf-1-Ct (M-Raf-1-Ct) and M-Raf-
1-Ct-K375A contain the yeast outer mitochondrial membrane
protein Mas70p transmembrane domain (residues 1–30) fused
to the N-terminus of Raf-1-Ct and Raf-1-Ct-K375A, respec-
tively. The Mas70p transmembrane domain was obtained by
amplifying the corresponding cDNA from yeast genomic
DNA with the primers 50-CCGAGAATTCATGAAGAG
CTTCATTACAAGGAACAAGAC-30 and 50-CGGGGTAC
CTCGTTGTTGTTGTTGTTGCAATTGGTT-30, and subse-
quently cloned as an EcoR1/Kpn1-fragment into pCAGGS-
Raf-1-Ct and pCAGGS-Raf-1-Ct-K375A. All the introduced
mutations and fusions were verified by sequencing on an
ABI373A sequencer (Applied Biosystems, Foster City, CA,
USA).
Cell culture and DNA transfection
The IL-3-dependent mouse pre-B cell line Ba/F3 (Palacios and
Steinmetz, 1985) was maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat-
inactivated fetal calf serum (FCS), 100U/ml penicillin,
100mg/ml streptomycin, and 10% conditioned medium from
WEHI-3B cells as a source of mouse IL-3. Ba/F3 cells were
stably transfected by electroporation as described (Cornelis
et al., 2000).
The L929sA TNF-sensitive mouse fibrosarcoma cell line was
cultured in DMEM with 10% heat-inactivated FCS, 1%
glutamine, 100U/ml penicillin and 100 mg/ml streptomycin.
L929sAhFas and L929sAhFas.Bcl-2 cells (cl. 6.11) are L929sA
cells that stably express the human Fas receptor (Vercammen
et al., 1998; Denecker et al., 2001), or the human Fas receptor
and the human Bcl-2 gene (Denecker et al., 2001), respectively.
FDCP-1 (Hapel et al., 1984), an IL-3-dependent mouse
myeloid progenitor cell line, was grown in RPMI-1640
medium supplemented with 10% FCS, 100U/ml penicillin,
100mg/ml streptomycin, and 10% conditioned medium from
WEHI-3B cells as a source of mouse IL-3.
Human embryonic kidney HEK293T cells (a gift from Dr M
Hall) were grown in DMEM supplemented with 10% (v/v)
heat-inactivated FCS, 100U/ml penicillin and 100 mg/ml
streptomycin. HEK293T cells were transiently transfected by
the calcium phosphate precipitation method. Transfected cells
were lysed in 25mM Tris phosphate (pH 8), 2mM DTT, 2mM
CDTA, 10% glycerol, and 1% Triton X-100. Firefly luciferase
activity was assayed in a total volume of 30ml. The reactions
were initiated by addition of 15 ml luciferase assay/substrate
buffer (40mM Tricine, 2mM [MgCO3]4Mg[OH]2, 5mM
MgSO4, 66mM DTT, 0.2mM EDTA, 0.5mM CoA, 1mM
ATP, 1mM D-luciferin) to 15ml cell lysate. Light emission was
detected by a Topcount scintillation counter. Activity of the b-
galactosidase transfection control was measured in a total
volume of 200ml. Cell lysate (20 ml) was added to 160 ml
substrate buffer (60mM Na2PO4, 10mM KCl, 1mM b-
mercaptoethanol), and the reaction was initiated by adding
20 ml of 50mM chlorophenolred-b-D-galactopyranoside sub-
strate.
Induction of apoptosis and measurement of DNA hypoploidy
Apoptosis was induced in L929sAFas cells by treatment with
100 ng/ml CH-11 anti-Fas antibody (BioCheck, Burlingame,
CA, USA). Apoptosis was induced in Ba/F3 cells by growth
factor withdrawal or by treatment with 1mg/ml puromycine
(Sigma, St Louis, MO, USA). In the former case, exponentially
growing cells were washed three times with serum-free medium
and seeded in DMEM supplemented with 10% FCS, either in
the absence or presence of 10% WEHI-3B cell-conditioned
medium. The apoptotic response was determined for each
stimulus by measuring the amount of hypoploid cells via flow
cytometry of propidium iodide stained cells that were
permeabilized by freeze-thawing.
Fluorimetric assay for caspase activity
Caspase-3 or -9 activity was measured by incubating 25 mg cell
lysate with respectively 50mM Ac-DEVD-amc or 50mM Ac-
LEHD-amc (Peptide Institute Osaka, Japan) in 150 ml of cell-
free system (CFS) buffer (10mM HEPES–NaOH pH 7.4,
220mM mannitol, 68mM sucrose, 2mM NaCl, 2.5mM
KH2PO4, 0.5mM EGTA, 2mM MgCl2, 5mM sodium pyr-
uvate, 0.1mM phenylmethylsulfonyl fluoride (PMSF), 1mM
dithiothreitol). The release of fluorescent 7-amino-4-methyl-
coumarin was monitored for 1 h at 371C at 2-min time
intervals in a fluorometer (Cytofluor, PerSeptive Biosystems,
Cambridge, MA, USA) at an excitation wavelength of 460 nm.
Data are expressed as the increase in fluorescence as a function
of time (DF/min).
In vitro caspase cleavage assays
Raf-1, Raf-1E-D273A, Raf-1E-D279A and Raf-1E-D337A in
pSV-Sport (1 mg) were used as template for in vitro coupled
transcription–translation in a reticulocyte lysate system
(Promega Biotec, Madison, WI, USA). Translation reactions
(2 ml) were incubated with 1U active recombinant human
caspase-9 (MBL, Naka-Ku Nagoya, Japan) in a total volume
of 25 ml CFS buffer for 1.5 h at 371C. In total, 1U of
recombinant caspase-9 is the enzyme activity that cleaves
1 nmol of the caspase substrate LEHD-pNA (pNA: pnitroa-
nilide) per hour at 371C at saturated substrate concentrations.
The resulting cleavage products were analysed by SDS–PAGE
and autoradiography.
Isolation of mitochondrial and cytosolic cell fractions
Exponentially growing Ba/F3 cells were washed three times
with serum-free medium and seeded in DMEM supplemented
with 10% FCS in the absence or presence of 10% WEHI-3B
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cell-conditioned medium. Cells were harvested after 20 h,
washed three times with buffer A (20mM MOPS, 1mg/ml
bovine serum albumin, 1mM EGTA, 100mM sucrose),
and resuspended in buffer B (buffer A plus 100mg/ml
digitonin, 0.1mM PMSF, 200U/ml aprotinin, 10 mg/ml
leupeptin, 1mM sodium orthovandate, 1mM sodium
fluoride). After homogenization (25 strokes with a dounce
homogenizer B pestle), samples were centrifuged twice (2500 g,
5min, 41C) to remove nuclei, and centrifuged again (10 000 g,
10min, 41C) to obtain the heavy membrane pellet. The
supernatant was centrifuged again (20 000 g, 10min, 41C)
and the soluble part was kept as the cytosol fraction. The
heavy membrane pellet was resuspended in 2ml of 15% Percoll
(v/v), and loaded on a Percoll gradient (60–40–23%). After
centrifugation (32 000 g, 5min, 41C), the mitochondrial frac-
tion was isolated and washed twice in CFS buffer. Finally, the
pellet was lysed in buffer containing 10mM Tris-HCl pH 7.4,
150mM NaCl, 5mM EDTA, 1% NP-40, 0.1mM PMSF,
200U/ml aprotinin, 10mg/ml leupeptin, 0.2mM sodium
orthovanadate and 1mM sodium fluoride. Protein samples
(50mg) of the different subcellular fractions were analysed by
Western blotting.
Immunoblot analysis
Cells were washed twice in ice-cold PBS, and equal cell
numbers were lysed by direct addition of protein loading
buffer (125mM Tris-HCl pH 6.8, 6% SDS, 1.4M b-mercap-
toethanol, 20% glycerol, 0.01% bromophenol blue) and
boiling for 5min. Cell lysates were separated by SDS–PAGE
and transferred onto a nitrocellulose membrane by semidry
blotting in a buffer containing 25mM Tris-HCl pH 8.0,
190mM glycine and 20% methanol. All further incubations
were carried out at room temperature on a platform shaker.
Blocking, incubation with antibody and washing of the
membrane were done in PBS supplemented with 0.05% Tween
20 (v/v) and 5% (w/v) nonfat dry milk. Primary antibodies
used were anti-Raf-1 (Raf-1 (C12), sc133, Santa Cruz, San
Diego, CA, USA), anti-mouse caspase-9, anti-Erk1/2 and anti-
phospho-Erk1/2 (Cell Signalling Technology, Beverly, MA,
USA), and anticytochrome oxidase subunit IV (COX IV)
(Molecular Probes, Eugene, OR, USA). Rabbit polyclonal
antibodies raised against recombinant murine caspases-3, -7
and -8 were prepared at the centre d’Economie Rurale
(Laboratoire d’Hormonologie Animale, Marloie, Belgium).
Membranes were incubated with horseradish peroxidase-
conjugated secondary antibodies against mouse and rabbit
immunoglobulin (Amersham Biosciences, Rainham, UK).
Immunoreactivity was revealed with the enhanced chemilumi-
nescence method (NEN Renaissance, PerkinElmer Life
Sciences Products).
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